- Home
- IRON vs VYX Comparison
IRON vs VYX Comparison
Compare IRON & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- VYX
- Stock Information
- Founded
- IRON 2017
- VYX 1881
- Country
- IRON United States
- VYX United States
- Employees
- IRON N/A
- VYX N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- VYX
- Sector
- IRON Health Care
- VYX
- Exchange
- IRON Nasdaq
- VYX Nasdaq
- Market Cap
- IRON 1.8B
- VYX 1.5B
- IPO Year
- IRON N/A
- VYX N/A
- Fundamental
- Price
- IRON $55.86
- VYX $13.30
- Analyst Decision
- IRON Strong Buy
- VYX Strong Buy
- Analyst Count
- IRON 11
- VYX 5
- Target Price
- IRON $92.64
- VYX $14.40
- AVG Volume (30 Days)
- IRON 390.2K
- VYX 1.8M
- Earning Date
- IRON 08-07-2025
- VYX 08-05-2025
- Dividend Yield
- IRON N/A
- VYX N/A
- EPS Growth
- IRON N/A
- VYX N/A
- EPS
- IRON N/A
- VYX 6.72
- Revenue
- IRON N/A
- VYX $2,733,000,000.00
- Revenue This Year
- IRON N/A
- VYX N/A
- Revenue Next Year
- IRON N/A
- VYX N/A
- P/E Ratio
- IRON N/A
- VYX $1.98
- Revenue Growth
- IRON N/A
- VYX N/A
- 52 Week Low
- IRON $30.82
- VYX $7.55
- 52 Week High
- IRON $68.73
- VYX $15.34
- Technical
- Relative Strength Index (RSI)
- IRON 61.10
- VYX 72.01
- Support Level
- IRON $52.70
- VYX $11.50
- Resistance Level
- IRON $55.26
- VYX $13.93
- Average True Range (ATR)
- IRON 2.42
- VYX 0.45
- MACD
- IRON 0.01
- VYX 0.11
- Stochastic Oscillator
- IRON 92.71
- VYX 73.46
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About VYX NCR Voyix Corporation
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.